ProtoKinetix Inc's business model revolves around the development and commercialization of innovative, proprietary anti-aging and regenerative medicine technologies. Leveraging their patented AAGP® (Anti-Aging Glycopeptide) technology, the company aims to enhance the performance and efficacy of various medical applications, including cell preservation, organ transplantation, and regenerative therapies. A key focus is on protecting and preserving living cells during medical procedures, leading to improved patient outcomes. By extensively researching and applying their cutting-edge technology, ProtoKinetix Inc strives to offer groundbreaking solutions that address critical healthcare needs.

ProtoKinetix Inc is primarily active in the fields of biotechnology and regenerative medicine. With its innovative AAGP® technology, the company aims to revolutionize various industries such as cell therapy, organ transplant, and cosmeceuticals. By leveraging its groundbreaking technology, ProtoKinetix Inc strives to improve healthcare by enabling successful cell survival, enhancing tissue regeneration, and promoting overall wellness. As a leader in the field, ProtoKinetix Inc continues to explore new applications and partnerships to drive advancements in the biotech and regenerative medicine sectors.

The main competitors of ProtoKinetix Inc in the market are companies such as Johnson & Johnson, Pfizer Inc., and Novartis AG.

ProtoKinetix Inc is a biotechnology company specializing in the development and commercialization of innovative therapeutic peptides. Founded in 2004, ProtoKinetix has been dedicated to advancing the applications of its AAGP™ (Anti-Aging Glycopeptide) technology. This unique peptide, derived from a natural protein, has shown promising results in various fields, including cell and organ transplants, regenerative medicine, and anti-aging therapies. With its cutting-edge research, ProtoKinetix aims to provide breakthrough solutions for addressing complex medical challenges and improving overall healthcare outcomes. The company continues to forge ahead in the realm of biotechnology, with a strong commitment to innovation and scientific excellence.

ProtoKinetix Inc, a leading biotech company, has achieved several significant milestones. The company successfully completed pre-clinical trials of its flagship product, AAGP®. ProtoKinetix Inc received positive results in these trials, demonstrating the product's ability to protect cells from damage and enhance cell functionality. This breakthrough technology has also been granted multiple patents, further solidifying its position in the market. Moreover, the company established strategic collaborations with renowned partners for the development and commercialization of AAGP® in various sectors, such as organ transplantation, stem cell therapy, and cosmetics. These milestones highlight ProtoKinetix Inc's dedication and advancements in providing innovative solutions for a diverse range of applications.

ProtoKinetix Inc is primarily present in several countries and regions around the world. The company operates in the United States, Canada, and Europe, with a strong presence in countries such as the United Kingdom, Germany, France, and Italy. Additionally, ProtoKinetix Inc has expanded its presence to other regions, including Asia, particularly in countries like China and Japan. With its global reach, ProtoKinetix Inc is able to cater to a diverse range of markets and leverage on international opportunities for growth and development.

ProtoKinetix Inc represents values of innovation, scientific advancement, and corporate responsibility. With a focus on developing and commercializing patented anti-aging glycopeptides, the company aims to revolutionize the fields of medicine, biotechnology, and regenerative medicine. ProtoKinetix Inc is committed to creating sustainable and cutting-edge solutions by leveraging their proprietary AAGP™ technology. By prioritizing research, development, and collaboration, ProtoKinetix Inc strives to make a positive impact on human health and improve quality of life.

Converted at the current exchange rate, the ProtoKinetix share trades at 0,01 EUR (0,01 USD).

ProtoKinetix Inc is a Canadian company specializing in the development of therapeutic technologies for a variety of applications. The company's core business is the production of biomimetic polymers for use in pharmaceuticals and medical devices. One of ProtoKinetix's main areas is the development of therapeutics for use in cell and tissue regeneration. The bioactive polymer platform AAGP (Anti-Aging Glycoprotein Polymers) is used to increase the survival rate of cells and tissues. This platform is unique in its ability to provide protection to cells and tissues and promote their regeneration. Another important area for ProtoKinetix is the development of devices for artificial organ simulation. The AAGP platform is used in combination with other high-performance polymers to ensure optimal device functionality. ProtoKinetix also offers a range of products for the agricultural industry. These are bio-stimulants for plants based on the AAGP platform. These products are designed to improve the growth rate and quality of plants while reducing the use of pesticides and other chemical agents. An important aspect of ProtoKinetix's business model is collaboration with industry partners to develop innovative technologies and products. The company works closely with leading academic institutions and government agencies to enhance the AAGP platform and develop new applications. ProtoKinetix holds a wide range of patents and intellectual property to protect its technologies and products. The company also has a strong partnership with the University of Alberta to promote research and development. In summary, ProtoKinetix's business model focuses on developing innovative therapeutics and devices for a variety of applications. The company relies on collaboration with renowned partners and has a wide range of intellectual property to protect its technologies and products. ProtoKinetix also has a strong presence in the agricultural industry, offering products to enhance the growth rate and quality of plants.

Liikevaihtoa ei voida laskea ProtoKinetix:lle tällä hetkellä.

Voittoa ei voida laskea ProtoKinetix:lle tällä hetkellä.

P/E-suhdetta ei voida laskea ProtoKinetix:lle tällä hetkellä.

P/S-suhdetta ei voida laskea ProtoKinetix:lle tällä hetkellä.

ProtoKinetix:n Eulpool-laatuscore on 2/10.

ProtoKinetix:n ISIN on US7437221002. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

ProtoKinetix:n WKN on 121605. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

ProtoKinetix:n ticker on PKTX. Tämä pörssinoteeraus käytetään ProtoKinetix-osakkeiden kauppaan pörssissä.

ProtoKinetix maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

ProtoKinetix kuuluu sektoriin 'Terveydenhuolto'.

ProtoKinetix:n osingot jaetaan valuutassa USD.